ConvaTec Group PLC (CNVVY)
- Previous Close
13.60 - Open
12.98 - Bid --
- Ask --
- Day's Range
12.98 - 12.98 - 52 Week Range
9.90 - 15.40 - Volume
20,580 - Avg. Volume
4,903 - Market Cap (intraday)
7.038B - Beta (5Y Monthly) 0.57
- PE Ratio (TTM)
51.92 - EPS (TTM)
0.25 - Earnings Date --
- Forward Dividend & Yield 0.25 (1.90%)
- Ex-Dividend Date Apr 25, 2024
- 1y Target Est
--
ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer. In addition, the company offers continence care products and services for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida, and other causes, as well as critical care devices and products used in intensive care units and hospital settings. Further, it provides infusion care solutions comprising disposable infusion sets for diabetes insulin pumps, or for pumps used in continuous subcutaneous infusion treatments for conditions such as parkinson's disease. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. ConvaTec Group PLC was founded in 1978 and is headquartered in London, the United Kingdom.
www.convatecgroup.com10,136
Full Time Employees
December 31
Fiscal Year Ends
Sector
Medical Instruments & Supplies
Industry
Recent News: CNVVY
Performance Overview: CNVVY
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CNVVY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CNVVY
Valuation Measures
Market Cap
7.04B
Enterprise Value
8.25B
Trailing P/E
51.51
Forward P/E
20.58
PEG Ratio (5yr expected)
2.15
Price/Sales (ttm)
3.11
Price/Book (mrq)
3.93
Enterprise Value/Revenue
3.85
Enterprise Value/EBITDA
18.12
Financial Highlights
Profitability and Income Statement
Profit Margin
6.08%
Return on Assets (ttm)
4.79%
Return on Equity (ttm)
7.89%
Revenue (ttm)
2.14B
Net Income Avi to Common (ttm)
130.3M
Diluted EPS (ttm)
0.25
Balance Sheet and Cash Flow
Total Cash (mrq)
98.3M
Total Debt/Equity (mrq)
77.53%
Levered Free Cash Flow (ttm)
204.15M
Company Insights: CNVVY
CNVVY does not have Company Insights
Research Reports: CNVVY
Analyst Report: ConvaTec Group PLC
Originally spun out of Bristol-Myers Squibb, Convatec designs, manufactures, and markets advanced wound care, ostomy, continence care, and infusion sets for the acute-care hospital and chronic-care home settings. Advanced wound care and ostomy supplies are the largest divisions, accounting for 33% and 29% of total revenue, respectively. Continence care has become a slightly smaller business (21% of revenue) following the decision to exit the acute care market, and infusion sets contribute 17% of consolidated revenue.
RatingPrice TargetAnalyst Report: ConvaTec Group PLC
Originally spun out of Bristol-Myers Squibb, Convatec designs, manufactures, and markets advanced wound care, ostomy, continence care, and infusion sets for the acute-care hospital and chronic-care home settings. Advanced wound care and continence care are the largest divisions, accounting for 30% and 26% of total revenue, respectively. Ostomy contributes 25% of revenue and infusion sets 19%.
RatingPrice TargetAnalyst Report: ConvaTec Group PLC
Originally spun out of Bristol-Myers Squibb, Convatec designs, manufactures, and markets advanced wound care, ostomy, continence care, and infusion sets for the acute-care hospital and chronic-care home settings. Advanced wound care and continence care are the largest divisions, accounting for 30% and 26% of total revenue, respectively. Ostomy contributes 25% of revenue and infusion sets 19%.
RatingPrice TargetAnalyst Report: ConvaTec Group PLC
Originally spun out of Bristol-Myers Squibb, Convatec designs, manufactures, and markets advanced wound care, ostomy, continence care, and infusion sets for the acute-care hospital and chronic-care home settings. Advanced wound care and continence care are the largest divisions, accounting for 30% and 26% of total revenue, respectively. Ostomy contributes 25% of revenue and infusion sets 19%.
RatingPrice Target